

## Scientific Poster Presentations II

**Monday, April 26, 2010**

**Hilton: Piedmont Ballroom**

**4:45 p.m. – 6:45 p.m.**

### ENCORE PRESENTATIONS:

Abstracts marked with an “E” are Encore Presentations. Encore presentations undergo the same peer review process as all other presentations, but they may have been presented elsewhere or published in abstract form prior to the 2010 Spring Practice and Research Forum.

### FINALISTS IN ABSTRACT AWARDS COMPETITION:

Abstracts marked with an “F” are finalists for the Best Paper, Best Resident and Fellow, and Best Student Poster awards. These papers were selected by a special panel of reviewers. The Best Resident and Fellow Poster and the Best Paper will be announced at 6:30 p.m., Monday, April 26, in the Piedmont Ballroom of the Hilton Hotel.

### ORIGINAL RESEARCH

#### ACCP Frontiers Career Development Award

1. Evaluation of a Novel Charcoal Cookie Formulation for Drug Adsorption.

*Wendy Klein-Schwartz, Pharm.D., MPH<sup>1</sup>, Doyon Suzanne, MD<sup>1</sup>, Thomas C. Dowling, Pharm.D, Ph.D<sup>2</sup>; (1)Maryland Poison Center, University of Maryland School of Pharmacy, Baltimore, MD; (2)University of Maryland, School of Pharmacy, Baltimore, MD*

#### Adult Medicine

2. Evaluation of hydration status of patients with hyperglycemia.

*Kurt A. Wargo, Pharm.D., BCPS<sup>1</sup>, Thomas M. English, Ph.D.<sup>2</sup>, Vishal Mandge, MD<sup>3</sup>, Mobin Shah, MD<sup>4</sup>, Robert Centor, MD<sup>3</sup>; (1)Auburn University Harrison School of Pharmacy, Huntsville, AL; (2)University of Alabama School of Medicine, Huntsville Regional Medical Campus, Huntsville, AL; (3)University of Alabama-Birmingham School of Medicine, Huntsville Regional Medical Campus, Huntsville, AL; (4)York Hospital, York, PA*

3. Impact of CIWA implementation in medically ill patients.

*Lindsay M. Arnold, Pharm.D.<sup>1</sup>, Keith Dunn, PharmD<sup>1</sup>, Andres Solorza, MD<sup>1</sup>, Jennifer Cunningham, RN, BSN<sup>2</sup>; (1)Boston Medical Center, Boston, MA; (2)Concord Hospital, Concord, NH*

4. Incidence, diagnoses, medication use, and outcomes of patients with Class III (morbid) obesity at a single academic medical center.

*Eli N. Deal, Pharm.D., James M. Hollands, Pharm.D., Scott T. Micek, Pharm.D.; Barnes-Jewish Hospital, Saint Louis, MO*

#### Ambulatory Care

5. Factors associated with medication record discrepancies in an ambulatory care setting.

*Autumn L. Runyon, PharmD.<sup>1</sup>, Kevin J. Lynch, PharmD, BCPS, MBA<sup>2</sup>; (1)Duquesne University, Mylan School of Pharmacy, Pittsburgh, PA; (2)Pfizer, Inc, Upper St. Clair, PA*

6. Seasonal variation in International Normalized Ratio impacts clinical management: the rise and fall of anticoagulation.

*Sarah M. Gadoua, PharmD<sup>1</sup>, Jennifer L. Clemente, PharmD<sup>1</sup>, Candice L. Garwood, Pharm.D.<sup>2</sup>, Peter Whittaker, PhD<sup>3</sup>; (1)Detroit Medical Center, Detroit, MI; (2)Wayne State University, Detroit, MI; (3)Wayne State University School of Medicine, Cardiovascular Research Institute and Dept of Emergency Medicine, Detroit, MI*

7. Healthy Outcome Partnership for Employees with diabetes (HOPE) program: Evaluation of an employer-sponsored diabetes management program.

*Virginia G. Williams, PharmD, Dave L. Dixon, PharmD, Debra J. Barnette, PharmD, James R. Beardsley, PharmD; Wake Forest University Baptist Medical Center, Winston Salem, NC*

#### Cardiovascular

8. Relationship between clopidogrel and cigarette smoking status in patients with acute coronary syndromes without ST-segment elevation myocardial infarction.

*Firoozeh S. Salek, PharmD, PhD; Robert Wood Johnson University Hospital, Rahway, NJ*

9. Clopidogrel and aspirin desensitization: clinical experience in a tertiary care center in cardiology.

*Julie Methot, B.Pharm., Ph.D.<sup>1</sup>, Marie-Pier Fournier, M.Sc.<sup>1</sup>, Karine Lejeune, M.Sc.<sup>1</sup>, Marie-Josée Boily, M.Sc.<sup>1</sup>, Jean Lefebvre, B.Pharm., Ph.D.<sup>2</sup>, Isabelle Taillon, M.Sc.<sup>1</sup>; (1)Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ), Québec, QC, Canada; (2)Université Laval, Quebec, QC, Canada*

10. High sensitivity C-reactive protein value in guiding statin therapy in a primary prevention population.

*Kristy H. Lucas, Pharm.D.<sup>1</sup>, B. Daniel Lucas Jr., Pharm.D.<sup>2</sup>, Mike Broce, MS<sup>2</sup>; (1)West Virginia University School of Pharmacy, Charleston, WV; (2)CAMC Health Education and Research Institute, Charleston, WV*

## Education/Training

15. Influence of introductory clinical experience on pharmacy students' self-confidence.

*Suzanne M. Rabi, PharmD, Susan L. Peverly, PhD, Nicholas G. Popovich, PhD; University of Illinois at Chicago, Chicago, IL*

16. Assessment of supplemental instruction in a new integrated infectious disease pharmacotherapy course.

*Elias B. Chahine, Pharm.D., BCPS, Jamie L. Fairclough, MPH, Ph.D., Christina B. Coakley, Pharm.D., Candidate; Palm Beach Atlantic University; Lloyd L. Gregory School of Pharmacy, West Palm Beach, FL*

17. Pharmacy student opinions of faculty drafted course packets for a pharmacotherapeutics course.

*Michael Steinberg, PharmD, Fae Wooding, PharmD, Kristine Willett, PharmD, Abir Kanaan, PharmD; Massachusetts College of Pharmacy and Health Sciences, Worcester, MA*

18. Academic performance in a pharmacotherapeutics course taught between two campuses utilizing distance education technology.

*Michael Steinberg, PharmD, Anna K. Morin, PharmD, Fae Wooding, PharmD, Kristine Willett, PharmD, Abir Kanaan, PharmD; Massachusetts College of Pharmacy and Health Sciences, Worcester, MA*

19. Evaluation of the impact of inpatient anticoagulation teaching practices on patient knowledge and readmission rates.

*Elizabeth A. Petrovitch, Pharm.D.<sup>1</sup>, Sheila M. Wilhelm, PharmD, BCPS<sup>2</sup>; (1)Harper University Hospital, Detroit, MI; (2)Wayne State University, Detroit, MI*

20E. Comparison of coverage of obesity and post-bariatric surgery medication-related issues in the curriculum.

*Angela R. Vinti, Pharm.D., BCPS, Kristi W. Kelley, Pharm.D., BCPS, CDE, Anne Marie Liles, Pharm.D., BCPS, Lea S. Eiland, Pharm.D., BCPS; Auburn University Harrison School of Pharmacy, Auburn, AL*

21E. Continuing professional development (CPD) compared to traditional continuing pharmacy education (CPE): A randomized, controlled trial.

*Karen J. McConnell, Pharm.D., Carey L. Newlon, RPh; Kaiser Permanente Colorado, Aurora, CO*

22E. Paediatric oncology patients' medication understanding and the relationship to quality of life.

*Tamara MacDonald, PharmD<sup>1</sup>, Bruce Crooks, MB, ChB<sup>1</sup>, Derek B. MacDonald, PhD-Candidate<sup>2</sup>, Cherie Collicott, medical, student<sup>3</sup>; (1)IWK Health Centre, Halifax, NS, Canada; (2)University of Georgia, Halifax, NS, Canada; (3)Dalhousie University, Halifax, NS, Canada*

23. Developing an interprofessional partnership to serve a community in need.

*Crystal Obering, PharmD, MBA, BCPS, Cameron C. Lindsey, PharmD, BC-ADM; University of Missouri Kansas City School of Pharmacy, Kansas City, MO*

## Family Medicine

25. Effectiveness of newer antidiabetic agents plus insulin in patients with type-2 diabetes.

*George Varghese, PharmD<sup>1</sup>, Sauri Catherine, MD<sup>1</sup>, Thomas Shank, PharmD<sup>2</sup>; (1)Brooke Army Medical Center, Fort Sam Houston, TX; (2)Pfizer Inc., San Antonio, TX*

## Health Services Research

28. How physicians and pharmacists communicate: Implications for patient safety.

*Alan J. Zillich, PharmD<sup>1</sup>, Heather A. Jaynes, MSN<sup>1</sup>, Andrew N. Schmelz, PharmD<sup>1</sup>, Jasmine D. Gonzalvo, PharmD<sup>1</sup>, Brad N. Doebbeling, MD<sup>2</sup>, Karen S. Hudmon, Dr.PH<sup>1</sup>, Richard M. Frankel, PhD<sup>2</sup>; (1)Purdue University, Indianapolis, IN; (2)Roudebush VA Medical Center, Health Services Research and Development Center of Excellence, Indianapolis, IN*

## Hematology/Anticoagulation

29. Acute kidney injury and response to warfarin: differential effects of initial INR.

*Carrie Molesa, PharmD<sup>1</sup>, Peter Whittaker, PhD<sup>2</sup>; (1)Harper Hospital, Detroit, MI; (2)Wayne State University School of Medicine, Cardiovascular Research Institute and Dept of Emergency Medicine, Detroit, MI*

## Nephrology

41. An assessment of different body weights and serum creatinine values used to estimate creatinine clearance.

*Sheila M. Wilhelm, PharmD, BCPS, Pramodini B. Kale-Pradhan, Pharm.D., Chris M. Herlehy, Pharm.D. Candidate; Wayne State University, Detroit, MI*

42. Evaluation of a new method of estimating kidney function for dosing antimicrobials.

*Kurt A. Wargo, Pharm.D., BCPS<sup>1</sup>, Thomas M. English, Ph.D.<sup>2</sup>; (1)Auburn University Harrison School of Pharmacy, Huntsville, AL; (2)University of Alabama School of Medicine, Huntsville Regional Medical Campus, Huntsville, AL*

43. Clinical outcomes associated with two Darbepoetin Alfa dosing strategies in hospitalized patients with anemia of chronic kidney disease requiring hemodialysis.

*Elvira C. Madueme, Pharm.D., BCPS, Barbara Hammer, Pharm.D., BCPS, Kim Corder, Pharm.D., Angel Hollrith,*

Pharm.D., Martin Webb, MD; Moses Cone Health System, Greensboro, NC

44. Measured creatinine clearance versus the modification of diet in renal disease and Cockcroft-Gault equations for renal function assessment and drug dosing recommendations.

*Amber E. King, Pharm.D.*<sup>1</sup>, Kishor Gandhi, M.D., M.P.H.<sup>2</sup>, Genevieve D'Souza, M.D.<sup>3</sup>, Cindy J. Wordell, B.S., Pharm.D., BCPS<sup>2</sup>, Eugene R. Viscusi, M.D.<sup>2</sup>; (1)Thomas Jefferson University, Philadelphia, PA; (2)Thomas Jefferson University Hospital, Philadelphia, PA; (3)Lucile Packard Children's Hospital at Stanford, Stanford, CA

45E. Effect of oral cromolyn sodium on CKD-associated pruritus and serum tryptase level: A double-blind placebo-controlled study.

*Ghazal Vessal, PharmD, PhD*, Mohammad Mehdi Sagheb, MD, Saman Shilian, PharmD, Payman Jafari, PhD, Soliman Mohammadi Samani, PharmD, PhD; Shiraz University of Medical Sciences, Shiraz, Iran

46E. Recombinant hirudin (lepirudin) use in patients with renal impairment and heparin-induced thrombocytopenia (HIT) type 2.

*Basirat O. Sanuth, PharmD, BCPS*<sup>1</sup>, Jessica J. Ellis, PharmD, BCPS<sup>1</sup>, Nina E. West, PharmD<sup>1</sup>, Jeffrey J. Ellis, PharmD, MS, BCPS<sup>2</sup>; (1)St Joseph Mercy Hospital, Ann Arbor, MI; (2)Trinity Health, Novi, MI

## Oncology

47. An evaluation of adverse interactions of 5-fluorouracil and capecitabine with warfarin.

*Sachin R. Shah, PharmD, BCOP*<sup>1</sup>, Randall Martin, Pharm.D.<sup>2</sup>, Jonathan Dowell, MD<sup>3</sup>, Sarah Gressett, Pharm.D.<sup>4</sup>; (1)VA North Texas Health Care System; Texas Tech University Health Sciences Center School of Pharmacy- Dallas/Ft. Worth Campus, Dallas, TX; (2)Texas Tech University Health Sciences Center, Dallas, TX; (3)University of Texas-Southwestern Medical Center, Dallas, TX; (4)Veterans Affairs North Texas Health Care System, Dallas, TX

## Pediatrics

48E. Omalizumab Reduces Asthma Exacerbations in Children (6-<12 Years) With Moderate-to-Severe Allergic (IgE-Mediated) Asthma Irrespective of Baseline LABA Use.

*Tracy Bridges, MD*<sup>1</sup>, J. Hebert, MD<sup>2</sup>, Angel Fowler-Taylor, RPh<sup>3</sup>, Carlos Fernandez Vidaurre, MD<sup>3</sup>, Indrias Berhane, PhD<sup>3</sup>; (1)Allergy & Asthma Clinics of Georgia, Albany, GA; (2)Centre de recherche appliquee en allergie de Quebec (CRAAQ), Quebec City, QC, Canada;

(3)Novartis Pharmaceuticals Corporation, East Hanover, NJ

## Pharmacoeconomics/Outcomes

49. Analysis of out-of-pocket expenditures of targeted oncologics in Medicare Part D-2009.

*Eve C. Elias, PharmD*; University of Missouri-Kansas City, Columbia, MO

50. Cost-effectiveness of current treatment options in treatment-resistant HIV/AIDS patients in the United States.

*Lieven Annemans, PhD, MSc*<sup>1</sup>, Andrew Hill, PhD<sup>2</sup>, Erik Smets, MSc, MBA<sup>3</sup>, Silas C. Martin, MS<sup>4</sup>, Michelle Cho, PharmD<sup>5</sup>, Joseph Mrus, MD, MSc<sup>5</sup>; (1)Ghent University, Gent, Belgium; (2)Pharmacology Research Laboratories, University of Liverpool, Liverpool, United Kingdom; (3)Johnson & Johnson Pharmaceutical Services LLC, Mechlen, Belgium; (4)Centocor Ortho Biotech Services, LLC, Horsham, PA; (5)Tibotec Therapeutics, Bridgewater, NJ

## Pharmacoepidemiology

51. Evaluating adverse drug events (ADEs) leading to emergency care.

*A. Thomas Taylor, Pharm.D.*<sup>1</sup>, Patrick F. Pratt, RPH, MBA<sup>2</sup>; (1)University of Georgia College of Pharmacy, Augusta, GA; (2)Doctors Hospital - Augusta, Augusta, GA

## Pharmacogenomics/Pharmacogenetics

52. Association between angiotensinogen genotype and aldosterone levels in heart failure.

*Larisa H. Cavallari, Pharm.D.*, Shitalben R. Patel, M.S., Vicki L. Groo, Pharm.D., Marlos A.G. Viana, Ph.D., Thomas D. Stamos, M.D.; University of Illinois at Chicago, Chicago, IL

## Pharmacokinetics/Pharmacodynamics

53. Fixed-Dose Combination Tablets of Saxagliptin and Metformin Extended Release (XR) are Bioequivalent to the Same Strengths of Concomitantly Administered Individual Tablets of Saxagliptin and Metformin XR.

*David Boulton, PhD*, Weijiang Zhang, Ph.D., Ming Chang, M.S., Li Li, Ph.D., Angela Tang, Pharm D., Cynthia Yones, R.N., Ernst U. Frevert, M.D., Vijay V. Upreti, Ph.D., Su Nam, M.D., Ph.D., Xiaohui Xu, Ph.D., Frank P. LaCreta, Ph.D., Chirag G. Patel, Ph.D.; Bristol-Myers Squibb Co. R&D, Princeton, NJ

54. Influence of pregnancy, race and oral contraceptive use on azithromycin pharmacokinetics in women of child bearing potential.

*Mitra Habibi, Pharm.D.<sup>1</sup>, Gloria Sarto, M.D., Ph.D.<sup>2</sup>, Keith A. Rodvold, Pharm.D.<sup>1</sup>, James H. Fischer, Pharm.D.<sup>1</sup>; (1)University of Illinois at Chicago, Chicago, IL; (2)University of Wisconsin, Madison, WI*

55. Fixed-dose Combination Tablets of Saxagliptin and Metformin Immediate Release (IR) are Bioequivalent to the Same Strengths of Concomitantly Administered Individual Tablets of Saxagliptin and Metformin IR in the Fed and Fasted States.

*David Boulton, PhD, Ming Chang, MS, Li Li, PhD, Donette Quamina-Edghill, MS, Bonnie Hsiang, MS, Su Nam, MD, PhD, Xiaohui Xu, PhD, Ernst U. Frevert, MD, Frank P. LaCreta, PhD, Vijay V. Upreti, PhD; Bristol-Myers Squibb Co. R&D, Princeton, NJ*

56E. Influence of Dosing Interval on Pharmacodynamic Susceptibility Profiles for Ciprofloxacin against *Pseudomonas aeruginosa*.

*S. Scott Sutton, Pharm.D.<sup>1</sup>, P. Brandon Bookstaver, PharmD<sup>1</sup>, James W. Hardin, PhD<sup>2</sup>; (1)University of South Carolina - South Carolina College of Pharmacy, Columbia, SC; (2)University of South Carolina, Biostatistics Collaborative Unit, Columbia, SC*

57. Stability and in vitro dissolution of D-Cycloserine capsules compounded to a strength of 50 mg.

*Wacharah Taupradist, PharmD, Candidate<sup>1</sup>, Demelash Alambo, PharmD, Candidate<sup>1</sup>, Cristian Sirbu, Ph.D.<sup>2</sup>, Gagan Kaushal, Ph.D.<sup>1</sup>; (1)University of Charleston, Charleston, WV; (2)West Virginia University School of Medicine, Charleston Area Medical Center, Charleston, WV*

## CLINICAL PHARMACY FORUM

### Adult Medicine

60. Accuracy of the Initial Medication History in Acutely Injured Patients.

*Eyad T. Almadhoun, clinical, pharmacist; Hamad Medical Corporation, Doha, Qatar*

61. Management of hyperglycemia in hospitalized patients.

*Bryan L. Love, PharmD, BCPS, Heather A. Kehr, PharmD, BCPS; Wingate University School of Pharmacy/Cabarrus Family Medicine Residency Program, Wingate, NC*

### Ambulatory Care

62. Utilizing Students in Home Based Primary Care to Maximize Patient Care in Veterans.

*Michelle S. Ho, Pharm.D.<sup>1</sup>, Jennifer H. Lai, Pharm.D.<sup>2</sup>, Khanh L. Nguyen, Pharm.D.<sup>3</sup>, Tim Chen, Pharm.D.<sup>3</sup>; (1)Veterans Affairs Palo Alto Health Care System, Palo Alto, CA; (2)University of California San Diego Medical*

*Center, San Diego, CA; (3)Veterans Affairs San Diego Healthcare System, San Diego, CA*

63. Implementation of a Tele-Health Lipid Clinic to achieve LDL goal among Veterans with Ischemic Heart Disease and Diabetes Mellitus.

*Timothy C. Chen, PharmD, Naureen Khan, Pharm.D., Nina Nguyen, Pharm.D., Canh Nguyen, Pharm.D., Joann Cheung, Pharm.D., Edna Ng-Chen, Pharm.D., Candace Eacker, Pharm.D., Tung Le, Pharm.D.; Veterans Affairs, San Diego, CA*

64. Development and implementation of a safety-net diabetes intensive care program.

*Sallie D. Mayer, PharmD, MBA, BCPS, Leticia R. Moczygamba, PharmD, PhD, Kai I Cheang, Pharm.D., M.S., BCPS; Virginia Commonwealth University School of Pharmacy, Richmond, VA*

65. A pharmacist's role in patient compliance with an Electronic Medication Management Assistant (EMMA) in a Warrior Transition Unit (WTU).

*J. Ashley Gunter, PharmD, Traci Brooks, PharmD, Ashley Hopper, PharmD; Womack Army Medical Center, Fort Bragg, NC*

66. Innovative Trial of Stand Alone Clinical Pharmacy Services Community Practice.

*Maria Teresa Ambrosini, Pharm.D.; Self Consultant, Breezy Point, NY*

67. IMPACT of process changes on cholesterol levels in a pharmacist-managed lipid clinic.

*Michael L. Neace, PharmD<sup>1</sup>, Carl J. Tullio, BS, MS, PharmD<sup>2</sup>; (1)1st Medical Group, Langley Air Force Base, VA; (2)Pfizer Inc, Yorktown, VA*

### Cardiovascular

68. How can we transition patients from intravenous to oral antihypertensives in the intensive care unit?.

*Christopher A. Paciullo, PharmD, Jessica Cabalza, MS4, Jerrold H. Levy, MD; Emory University Hospital, Atlanta, GA*

69. Multi-site evaluation of adult hospital patients with acute decompensated heart failure (ADHF) receiving nesiritide compared with loop diuretics.

*Charlene A. Hope, PharmD, BCPS<sup>1</sup>, Haleh Maali, PharmD, Candidate<sup>2</sup>, Nicolas VanGompel, PharmD, Candidate<sup>2</sup>; (1)Comprehensive Pharmacy Services, Memphis, TN; (2)Midwestern University, Downers Grove, IL*

70. Design and Implementation of a Pharmacist-Managed 24-hour Ambulatory Blood Pressure Monitoring Service in an Outpatient Cardiology Clinic.

*Kade T. Birkeland, Pharm.D.<sup>1</sup>, Nishi Patel, Pharm.D., Candidate<sup>2</sup>, David Parra, Pharm.D., FCCP, BCPS<sup>1</sup>; (1)The*

Department of Veterans Affairs Medical Center, West Palm Beach, FL; (2)University of Minnesota College of Pharmacy Duluth, Duluth, MN

### **Clinical Administration**

71. Documenting value added clinical pharmacy services in a small rural hospital.

*Philip D. Rolland, Pharm.D., M.H.A.*; Byrd Regional Hospital, Leesville, LA

72E. Protected Professional Practice Evaluation: A Continuous Quality Improvement Process.

*Stuart T. Haines, Pharm.D., BCPS*, Rhonda A. Ammann, Pharm.D., Donna M. Beehrle-Hobbs, Pharm.D., Julie Groppi, PharmD, CDE; West Palm Beach VA Medical Center, West Palm Beach, FL

73. Initiation of Clinical Pharmacy Service into a Warrior Transition Clinic at an Army Medical Treatment Facility.

*Traci C. Brooks, PharmD*, J. Ashley Gunter, PharmD, Ashley Hopper, PharmD; Womack Army Medical Center, Fort Bragg, NC

74. Implementation of clinical pharmacy services in a community hospital: Converting from a product to patient centered model.

*Priyesh G. Patel, Pharm.D., MBA<sup>1</sup>*, Benjamin J Staley, Pharm.D.<sup>1</sup>, Steven G. Pickette, B.S.Pharm, BCPS<sup>2</sup>; (1)Providence St. Peter Hospital, Olympia, WA; (2)Providence Health System, Renton, WA

### **Education/Training**

79. Use of blogging to enhance clinical reflection during Introductory Pharmacy Practice Experiences.

*Katie S. McClendon, Pharm.D.<sup>1</sup>*, James J. Pitcock, PharmD<sup>1</sup>, Margaret B. Pitcock, PharmD<sup>2</sup>; (1)University of Mississippi School of Pharmacy, Jackson, MS; (2)VA Medical Center, Jackson, MS

80. Application of Course Content and Development of Patient Education and Counseling Skills for First Year Pharmacy Students in a Non-Prescription Drug Simulation Lab.

*George A. DeMaagd, Pharm., D, BCPS*, Kim Jones, Pharm.D, BCPS, Lauren Peyton, Pharm.D., Kim Lindsey, Pharm.D, BCPS, Mark Stephens, Pharm.D, BCPS, Andrew Martin, Pharm.D, Dave Kuhl, Pharm.D, Sheila Mitchell, Pharm.D.; Union University School of Pharmacy, Jackson, TN

81. Didactic and experiential curriculum: Recommendations from The Strategic Planning Summit of Pain and Palliative Care Pharmacy.

*M. Lynn McPherson, PharmD<sup>1</sup>*, Chris M. Herndon, PharmD<sup>2</sup>; (1)University of Maryland School of Pharmacy,

Baltimore, MD; (2)Southern Illinois University Edwardsville, Edwardsville, IL

82. Impact of pharmacist documentation of core measures in congestive heart failure patients in a level II trauma, community teaching hospital.

*Jennifer E. Reel, PharmD*, Melissa M. Blair, Pharm.D., BCPS, FCCP, CDE; New Hanover Regional Medical Center, Wilmington, NC

83. Practice-site dependent competencies in a certificate program: Recommendations from The Strategic Planning Summit for Pain and Palliative Care Pharmacy.

*Scott Strassels, PharmD, PhD<sup>1</sup>*, Chris M. Herndon, PharmD<sup>2</sup>; (1)University of Texas, Austin, TX; (2)Southern Illinois University Edwardsville, Edwardsville, IL

### **Health Services Research**

89. Benchmarking attempt for restricted antimicrobial agents in Lebanon.

*Ulfat M. Usta, MS, Clinical, Pharmacy, BCNSP<sup>1</sup>*, Latife Karam, PharmD<sup>2</sup>, Maguy Abou Selwan, Pharm D<sup>2</sup>; (1)American University of Beirut, Beirut, Lebanon; (2)Hotel Dieu de France, Beirut, Lebanon

### **Hematology/Anticoagulation**

90. Practice change to include accountability for outcome measures.

*Jean B. Douglas, BS, Pharm, PharmD*, Jacqueline M. Roh, BS Pharm, James B. Groce, BS Pharm, PharmD, Jennifer D. Durham, PharmD, Kimberly B. Hammons, PharmD, Andrew D. Meyer, PharmD, Marsena Pardee, MSN, Justin Legge, PharmD, Jan Stafford, BS, Pharm, Clinton M. Young, MD, William Bowman, MD; Moses Cone Health System, Greensboro, NC

91. Impact of a venous thromboembolism prophylaxis program on events and prophylaxis rates.

*Bebbyn A. Schafer, PharmD<sup>1</sup>*, April D. Miller, PharmD, BCPS<sup>2</sup>, Chris Carter, PharmD<sup>1</sup>; (1)Palmetto Health Richland, Columbia, SC; (2)South Carolina College of Pharmacy-USC Campus, Columbia, SC

### **Oncology**

97. Evaluation of clinical pharmacy services in an Oncology outpatient setting.

*Hyunjeong Im, Pharm.D., BCOP*, Eugene Kim, BS, Youngsoon Kim, BS, Seonyoung Chung, MS, Yongwon In, MS, Kieho Sohn, Ph.D.; Samsung Medical Center, Department of Pharmacy, Seoul, South Korea

## RESIDENTS AND FELLOWS RESEARCH IN PROGRESS

### Ambulatory Care

102. Assessment of clinical and humanistic outcomes of a managed care value-based medication management program for uncontrolled hypertension patients.

*Jessica L. Varner, Pharm.D.*, Elizabeth E. Floyd, Pharm.D., Patricia A. Tabor, Pharm.D., Paul J. Godley, Pharm.D.; Scott and White Health Plan, Temple, TX

103. Assessment of diabetes preventive care in a pharmacy-based member benefit medication management program.

*Candace M. Kuhl, Pharm.D.*, Elisa Muska, Pharm.D., Yoona Kim, Pharm.D., Patricia A. Tabor, Pharm.D., Joyce Juan, Pharm.D., Paul J. Godley, Pharm.D.; Scott & White Health Plan, Temple, TX

104. Effectiveness of a pharmacy care management program for veterans with hypertension.

*Andrew N. Schmelz, PharmD<sup>1</sup>*, Susan Bex, PharmD, BCPS<sup>2</sup>, Amy Boldt, PharmD<sup>2</sup>, Sarah Binkley, PharmD<sup>2</sup>, Stacy Bolf, PharmD, BCPS<sup>2</sup>, Cassandra Walston, PharmD, BCPS<sup>2</sup>, Darin Ramsey, PharmD, BCPS<sup>2</sup>, Alan J. Zillich, PharmD<sup>1</sup>; (1)Purdue University, Indianapolis, IN; (2)Richard L. Roudebush VA Medical Center, Indianapolis, IN

105. Implementation and reliability of a depression protocol in an outpatient internal medicine diabetes population.

*Katherine R. Gerrald, PharmD, BCPS<sup>1</sup>*, Betsy B. Shilliday, PharmD, CDE, CPP<sup>2</sup>, Timothy J. Ives, PharmD, MPH, BCPS, FCCP, CPP<sup>2</sup>, Robert M. Malone, PharmD, CDE, CPP<sup>1</sup>; (1)UNC Hospitals, Chapel Hill, NC; (2)University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC

### Cardiovascular

106. Prescribing patterns of proton pump inhibitors in patients requiring clopidogrel post drug eluting stent.

*Megan E. Musselman, Pharm.D.*, Adam J. Bursua, Pharm.D., Robert J. DiDomenico, Pharm.D., Adhir Shroff, M.D., Vicki L. Groo, Pharm.D.; University of Illinois at Chicago, Chicago, IL

107. Evaluation of Endothelial Function Using Peripheral Arterial Tonometry in Coronary Artery Disease Patients Treated for Depression.

*Kyle J. Ellis, Pharm.D.<sup>1</sup>*, Almasa Bass, Pharm.D.<sup>1</sup>, Bryant Tran, Pharm.D.<sup>1</sup>, Melissa Caughey, R.V.T.<sup>2</sup>, George A. Stouffer, M.D.<sup>2</sup>, Alan L. Hinderliter, M.D.<sup>2</sup>, Craig R. Lee, Pharm.D., Ph.D.<sup>1</sup>; (1)Eshelman School of Pharmacy University of North Carolina Chapel Hill, Chapel Hill,

NC; (2)School of Medicine, Division of Cardiology, UNC at Chapel Hill, Chapel Hill, NC

108. Warfarin prescribing in atrial fibrillation.

*Kena J. Lanham, PharmD<sup>1</sup>*, Douglas T. Steinke, PhD.<sup>2</sup>, Jeffrey C. Talbert, PhD.<sup>2</sup>, Steven P. Dunn, PharmD<sup>1</sup>, Ann M. Wiesner, Pharm.D.<sup>3</sup>, Aimee G. Adams, Pharm.D.<sup>1</sup>, Claude S. Elayi, MD<sup>1</sup>, Tracy E. Macaulay, PharmD<sup>1</sup>; (1)University of Kentucky HealthCare, Lexington, KY; (2)University of Kentucky College of Pharmacy, Lexington, KY; (3)Virginia Commonwealth University, Richmond, VA

109. The relationship between gender and mortality in Kentucky Medicaid heart failure patients.

*Komal A. Pandya, Pharm.D.<sup>1</sup>*, Tracy E. Macaulay, Pharm.D., BCPS<sup>2</sup>, Douglas T. Steinke, PhD.<sup>3</sup>, Jeffrey C. Talbert, PhD.<sup>4</sup>, Alison Bailey, MD<sup>1</sup>; (1)UK Healthcare, Lexington, KY; (2)University of Kentucky HealthCare, Lexington, KY; (3)UKHealthCare, Lexington, KY; (4)University of Kentucky College of Pharmacy, Lexington, KY

110. Utilization of P2Y12 testing and its impact on therapeutic decision making.

*Jeffrey Lalama, Pharm.D.<sup>1</sup>*, Marcia L. Brackbill, Pharm.D.<sup>2</sup>; (1)Winchester Medical Center, Winchester, VA; (2)Shenandoah University, Bernard J. Dunn School of Pharmacy, Winchester, VA

111. Observational data on the use of a heparin correlation for managing heparin nomograms.

*Abigail E. Miller, PharmD, BCPS*, Deborah Montague, PharmD, MS, BCPS, AQ, Cardiology; University of North Carolina Hospitals, Chapel Hill, NC

112. Evaluation of glucose control in cardiac intensive care unit patients following myocardial infarction.

*Katherine M. Carey, PharmD*, Jennifer L. Donovan, PharmD, Matthew A. Silva, PharmD, BCPS, Brian S. Smith, PharmD, BCPS, Maichi T. Tran, PharmD, BCPS; UMass Memorial Medical Center, Worcester, MA

113. A cost evaluation of bivalirudin, eptifibatide, and enoxaparin during percutaneous coronary intervention in a community hospital.

*Krisan Anderson, Pharm, D<sup>1</sup>*, Cara L. Léos, Pharm, D, BCPS<sup>2</sup>; (1)East Alabama Medical Center and Auburn University Harrison School of Pharmacy, Opelika, AL; (2)Auburn University Harrison School of Pharmacy, Auburn University, AL

### Community Pharmacy Practice

114. An analysis of economic outcomes following pharmacist-provided medication therapy management services.

Ashley R. Branham, PharmD<sup>1</sup>, Stefanie P. Ferreri, PharmD, CDE<sup>1</sup>, Joseph S. Moose, PharmD<sup>2</sup>, Macary Marciniak, PharmD, BCPS<sup>1</sup>; (1)UNC Eshelman School of Pharmacy, Chapel Hill, NC; (2)Moose Professional Pharmacy, Concord, NC

115. Assessing patient satisfaction of pharmacist-initiated counseling in a community setting.

Renee M. Alsberry, Doctor, of, Pharmacy<sup>1</sup>, Jamie Kearns, Doctor of Pharmacy<sup>1</sup>, Kevin J. Lynch, PharmD, BCPS<sup>2</sup>, Thomas Mattei, Doctor of Pharmacy<sup>1</sup>, Debbie Krasnow, Doctor, of, Pharmacy<sup>3</sup>; (1)Duquesne University, Pittsburgh, PA; (2)Pfizer, Inc, Upper St. Clair, PA; (3)Giant Eagle Pharmacy, Pittsburgh, PA

116. Evaluation of clinical outcomes of a member benefit medication management program for high risk managed care patients with diabetes.

Elisa Muska, Pharm.D., Candace M. Kuhl, Pharm.D., Patricia A. Tabor, Pharm.D., BCPS, Paul J. Godley, Pharm.D., FASHP, Joyce Juan, Pharm.D., Yoon Kim, Pharm.D.; Scott & White Health Plan, Temple, TX

## Education/Training

123. Assessing the need for pharmacogenomic education in pharmacy point-of-care providers.

Kristen B. McCullough, Pharm.D., Christine M. Fornea, Pharm.D., Kevin D. Berg, R.Ph., Julianna A. Burzynski, Pharm.D., Julie L. Cunningham, Pharm.D., Lynn L. Estes, Pharm.D., Narith N. Ou, Pharm.D., Maria I. Rudis, Pharm.D., Joanna L. Stollings, Pharm.D., Wayne T. Nicholson, M.D., Pharm.D.; Mayo Clinic Rochester, Rochester, MN

124. Impact of pharmacist interventions on meeting the core measure requirement of appropriate initial antibiotic selection for community-acquired pneumonia patients in a level II trauma, community teaching hospital.

Laurie M. Whalin, BS, PharmD, Jenna Reel, PharmD, BCPS, Melissa M. Blair, PharmD, FCCP, FASHP, BCPS, CDE ; New Hanover Regional Medical Center, Wilmington, NC

125. Enhancing tobacco cessation counseling among cancer care providers through web-based learning.

Andrew N. Schmelz, PharmD, Alan J. Zillich, PharmD, Christine Fenlon, BFA, Karen S. Hudmon, DrPH; Purdue University, Indianapolis, IN

126. Post-PharmD Industry Fellowships: An Analysis of the Currently Available Programs and Post-Graduate Career Opportunities.

Stephanie N. Melillo, PharmD, James Scanlon, Pharm.D., Amy Gangadharan, PharmD, Raymond P. Kim, PharmD; Massachusetts College of Pharmacy and Health Sciences, Worcester, MA

127. Use of a self-directed learning readiness scale (SDLRS) to predict performance in a doctor of pharmacy abilities lab course.

Zachariah M. Deyo, PharmD, Charmaine D. Rochester, PharmD, BCPS, CDE, Deborah A. Sturpe, PharmD, BCPS, Donna Huynh, PharmD, BCPS, MA, Katie Kiser, PharmD, BCPS; Univeristy of Maryland School of Pharmacy, Baltimore, MD

## Family Medicine

130. Effect of pharmacist intervention on medication use and healthcare resource utilization at transitions of care.

Whitney Maxwell, Pharm.D., BCPS<sup>1</sup>, Sarah K. Ford, Pharm.D., BCPS<sup>1</sup>, C. Brock Woodis, Pharm.D., BCPS<sup>1</sup>, Samuel Weir, M.D.<sup>2</sup>, Kathleen Barnhouse, M.D.<sup>2</sup>; (1)University of North Carolina Hospitals Department of Pharmacy (UNC), Chapel Hill, NC; (2)University of North Carolina Department of Family Medicine, Chapel Hill, NC

## Hematology/Anticoagulation

134. Tuberculosis and diabetes: blood glucose level and leukocytes count are they correlated?

Daud Moalin Ishaq, PhD, Student, Syed Azhar Sulaiman, Assoc., Prof; Universiti Sains Malaysia, Penang

135. Venous thromboembolic events during hospitalization in patients that missed doses of pharmacologic venous thromboembolism prophylaxis.

Valerie Shafir, Pharm.D., Peggy S. Kraus, Pharm.D., CACP, Brian Pinto, Pharm.D., MBA, Kenneth M. Shermock, Pharm.D., PhD, Michael B. Streiff, M.D.; The Johns Hopkins Hospital, Baltimore, MD

136. Evaluation of the Use of Phytonadione in Warfarin Reversal at a Community Hospital.

Darowan Akajagbor, Pharm.D., Valery L. Chu, Pharm.D., CACP, Henry Cohen, MS, Pharm.D., FCCM, BCPP, CGP; Kingsbrook Jewish Medical Center and Arnold & Marie Schwartz College of Pharmacy and Health Sciences of Long Island University, Brooklyn, NY

137. Does a standardized warfarin dosing protocol reduce patient bleeding and thromboembolic events?.

Austin R. Satterthwaite, PharmD<sup>1</sup>, Maichi T. Tran, Pharm.D., BCPS<sup>1</sup>, Yelena E. Kier, DO<sup>1</sup>, Jennifer L. Donovan, PharmD<sup>2</sup>; (1)UMass Memorial Medical Center, Worcester, MA; (2)Umass Memorial Medical Center, Worcester, MA

138. Evaluation of a heparin induced thrombocytopenia (HIT) guideline at an academic medical center.

Kathryn M. Ruf, PharmD, Daniel A. Lewis, PharmD, BCPS, Jeremy D. Flynn, PharmD, BCPS, George A. Davis, PharmD, BCPS; UK HealthCare, Lexington, KY

139. An evaluation of pharmacy intervention on the prescribing of vitamin K and associated length of stay in a community hospital setting.

*Laura K. Cummings, Pharm, D<sup>1</sup>*, Cara L. Léos, Pharm, D, BCPS<sup>2</sup>; (1)East Alabama Medical Center and Auburn University Harrison School of Pharmacy, Opelika, AL; (2)Auburn University Harrison School of Pharmacy, Auburn University, AL

### Men's Health

150. From fruit extract to structure activity relationship studies: Dietary xanthenes isolated from the mangosteen fruit for prostate cancer chemoprevention.

*Jeremy J. Johnson, PharmD<sup>1</sup>*, Deeba N. Syed, MBBS<sup>2</sup>, John T. Rasmussen, PharmD(candidate)<sup>1</sup>, Hasan Mukhtar, PhD<sup>2</sup>; (1)University of Wisconsin School of Pharmacy, Madison, WI; (2)University of Wisconsin School of Medicine and Public Health, Madison, WI

### Nephrology

151. Use of erythropoietin stimulating agents in hospitalized patients with end stage renal disease receiving dialysis.

*Melissa A. Nestor, PharmD<sup>1</sup>*, Val R. Adams, PharmD, BCOP, FCCP<sup>2</sup>, Kevin Harned, MD<sup>3</sup>, Daniel A. Lewis, PharmD, BCPS<sup>1</sup>, P. Shane Winstead, PharmD<sup>1</sup>, George A. Davis, PharmD, BCPS<sup>1</sup>; (1)University of Kentucky HealthCare, Pharmacy Services, Lexington, KY; (2)University of Kentucky College of Pharmacy, Lexington, KY; (3)University of Kentucky HealthCare, Department of Nephrology, Lexington, KY

### Oncology

152. Quantifying and understanding outpatients adherence to oral antineoplastic treatments: an Italian single institution survey.

*Elena Giubellino, PhD*, Cristiano Oliva, MD, Alessandro Comandone, MD, PhD; Gradenigo Hospital, Turin, Italy

### Pediatrics

153. An evaluation of the accuracy of Neofax gentamicin dosing recommendations; are targets met?.

*Allison B. Blackmer, PharmD, BCPS*, Elizabeth A. Farrington, PharmD, FCCP, FCCM, BCPS; University of North Carolina Hospitals, Chapel Hill, NC

154. Using a classification of errors to improve decision support in computerized prescriber order entry in neonates with renal dysfunction.

*Sandra S. Garner, Pharm.D.<sup>1</sup>*, Toby H. Cox, Pharm.D.<sup>2</sup>, *Jessica Golden, Pharm.D.<sup>2</sup>*, Michael G. Irving, MS, BS<sup>2</sup>, Elizabeth G. Hill, Ph.D.<sup>2</sup>, Robin Bissinger, Ph.D., NNP<sup>2</sup>, David J. Annibale, M.D.<sup>2</sup>; (1)South Carolina College of

Pharmacy, Charleston, SC; (2)Medical University of South Carolina, Charleston, SC

155. Utilization, adverse event, and cost trends associated with watchful waiting in the treatment of acute otitis media.

*Kimberly Van Wyk, Pharm.D.*, Brooke Pugmire, Pharm.D., Rex Force, PharmD; Departments of Family Medicine and Pharmacy Practice, Idaho State University, Pocatello, ID

156. Assessment of medication-related falls in children in a level one trauma center.

*Evgeny Gorodetsky, PharmD<sup>1</sup>*, Kimberly A. Pesaturo, PharmD., BCPS<sup>2</sup>, Brian S. Smith, PharmD., BCPS<sup>1</sup>, Christian A. Hartman, PharmD., MBA<sup>1</sup>; (1)UMass Memorial Medical Center, Worcester, MA; (2)Massachusetts College of Pharmacy and Health Sciences, Worcester, MA

### Pharmacoeconomics/Outcomes

157. Conversion from donepezil to galantamine extended-release: evaluation of the safety and efficacy of a cost savings initiative.

*Amy Henneman, Pharm.D.*, Cherylyn Beckey, Pharm.D., BCPS, CDE, Rob Hough, Pharm.D., Nahla Lutfi, Pharm.D., BCPS; West Palm Beach VA Medical Center, West Palm Beach, FL

### Pharmacoepidemiology

158. Follow-up care after acute asthma events.

*John T. Holmes, Pharm.D.*, Brooke Pugmire, Pharm.D., Rex W. Force, Pharm.D.; Departments of Family Medicine and Pharmacy Practice, Idaho State University, Pocatello, ID

159. Acute asthma events and prior use of inhaled corticosteroids.

*John T. Holmes, Pharm.D.*, Brooke Pugmire, Pharm.D., James G. Jepson, Pharm.D., Candidate, Vaughn L. Culbertson, Pharm.D.; Departments of Family Medicine and Pharmacy Practice, Idaho State University, Pocatello, ID

### Pharmacokinetics/Pharmacodynamics

160. Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation.

*Kelly A. Walsh, PharmD*, Robert J. Kuhn, PharmD, George A. Davis, PharmD, BCPS, Kyle A. Weant, PharmD, BCPS, Don Hayes Jr., MD, Jeremy D Flynn, PharmD, BCPS; University of Kentucky HealthCare, Lexington, KY

## LATE BREAKERS

### ADR/Drug Interactions

218. Angioedema after Non-Steroidal Anti-Inflammatory Drug initiation in a patient stable on an Angiotensin-Converting Enzyme Inhibitor.

*Roda Plakogiannis, B.S., Pharm.D., BCPS, CLS<sup>1</sup>, Lendita Prlesi, PharmD<sup>2</sup>; (1)Arnold & Marie Schwartz College of Pharmacy, Brooklyn, NY; (2)Montefiore Medical Center, Bronx, NY*

### Cardiovascular

219. Collaborative management of Heart Failure (HF) patients at the Portland Veterans Affairs Medical Center (VAMC).

*Harleen Singh, Pharm.D., BCPS<sup>1</sup>, Jessina C. McGregor, PhD<sup>1</sup>, Lisa Perry, BS<sup>1</sup>, Sharon Shiraga, BA<sup>1</sup>, Sydney Holt, BS<sup>1</sup>, Greg C. Larsen, MD<sup>2</sup>; (1)Oregon State University/Oregon Health & Science University College of Pharmacy, Portland, OR; (2)Portland Veterans Affairs Medical Center (VAMC), Portland, OR*

### Critical Care

220. Assessment of subcutaneous insulin on glycemic control in the intensive care setting using a computerized GlucoStabilizer<sup>®</sup> program.

*Serena A. Harris, PharmD, Sarah A. Nisly, PharmD, BCPS, Laura E. Aykroyd, PharmD, BCPS, Rattan V. Juneja, MBBS, MD, MRCP, Brian J. Ulmer, MD, Joni T. Carroll, RN, CDE; Clarian Health Partners, Indianapolis, IN*

### Education/Training

221. Evaluating pharmacy student understanding of literature evaluation to improve drug information application.

*Jean E. Cunningham, PharmD, Laura Perry, PharmD; The University of Findlay College of Pharmacy, Findlay, OH*

### Family Medicine

222. Survey of patients' and physicians' satisfaction with a pharmacist managed anticoagulation program in a family medicine clinic.

*Lisa D. Bishop, BSc(Pharm), Pharm.D., Stephanie W. Young, BSc(Pharm), Pharm.D., MSc(Med), Carla M. Dillon, BSc(Pharm), Pharm.D., Laurie Twells, PhD, John J. Hawboldt, BSP, Pharm.D.; School of Pharmacy, Memorial University, St. John's, NF, Canada*

### Hematology/Anticoagulation

223. Risk of venous thromboembolism as a function of international normalized ratio in total hip replacement.

*Sumesh Kachroo, PhD, MS<sup>1</sup>, Beth L. Nordstrom, PhD, MPH<sup>1</sup>, Edith A. Nutescu, Pharm.D.<sup>2</sup>, Jeff Schein, DrPH, MPH<sup>3</sup>, Alan Fisher, DrPH<sup>3</sup>, Brahim Bookhart, MBA, MPH<sup>3</sup>; (1)United Biosource Corporation, Lexington, MA; (2)University of Illinois at Chicago, Chicago, IL; (3)Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ*

### Infectious Diseases

224. Evaluation of Acinetobacter infection.

*Sarah B. Nelson, Pharm.D., Teresa G. Potter, PharmD, MPH; Virginia Commonwealth University Health System, Richmond, VA*

### Oncology

225. Development of chemotherapy protocols in an integrated healthcare delivery hospital.

*Yu-Hsuan Yen, MS; Taipei Medical University - Wanfang Hospital, Taipei, Taiwan*

### Pain Management/Analgesia

226. Hospital Pain Management: Identifying System Failures and Demystifying Pain Control.

*Barbara J. Ailor, PharmD, MS, BS, Maureen A Kochen, BSN, MBA, Linda L Norris, BS, CPHQ, CPMSM, Sabira V Tejani, MD; Los Alamitos Medical Center, Los Alamitos, CA*

### Pediatrics

227. Improving prophylactic treatment of patent ductus arteriosus in premature neonates.

*Varsha Bhatt-Mehta, MS, (CRDSA), Pharm.D., FCCP, Robert E. Schumacher, MD, Janice Wojtecki, Pharm.D. Candidate, Susan Hieber, RRT, MA, Mohammad Attar, MD; University of Michigan, Ann Arbor, MI*

### Pharmacoeconomics/Outcomes

228. Pharmaceutical Costs MANAGEMENT:

Thalidomide Tablet'S USE IN PATIENTS with MM. Anna Bianca Calzona, pharmacy<sup>1</sup>, Daniela Chequolo, pharmacy<sup>2</sup>, Rossella Distilo, pharmacy<sup>2</sup>, Simona Ferraiuolo, pharmacy<sup>2</sup>, Giovanni Guarany, pharmacy<sup>2</sup>, Grazia Mingolla, PHARMACY<sup>2</sup>, Renato Lisitano, pharmacy<sup>2</sup>, Gerardo Miceli Sopo, pharmacy<sup>3</sup>, Daniela Scolaro, pharmacy<sup>2</sup>, Roberto Tazza, pharmacy<sup>2</sup>; (1)ASL ROMA B, Rome, Italy; (2)Sandro Pertini Hospital, Rome, Italy; (3)ASL ROMA D, Ostia, Italy

229. Methadone SYRUP PREPARATION IN Pharmacy: Costs MANAGEMENT.

*Chequolo Daniela, pharmacy<sup>1</sup>, Distilo Rossella, pharmacy<sup>1</sup>, Ferraiuolo Simona, pharmacy<sup>1</sup>, Guarany*

Giovanni, pharmacy<sup>1</sup>, Lisitano Renato, pharmacy<sup>1</sup>, Miceli Sopo Gerardo, pharmacy<sup>2</sup>, *Grazia Mingolla*, PHARMACY<sup>1</sup>, Scolaro Daniela, pharmacy<sup>1</sup>, Tazza Roberto, pharmacy<sup>1</sup>; (1)Sandro Pertini Hospital, Rome, Italy; (2)ASL RMD, Rome, Italy

230. Impact of computerized physician order entry (CPOE) on the use of levalbuterol.

*Heather M. Rouse, Pharm.D.*<sup>1</sup>, Edward Seidl, PharmD<sup>2</sup>; (1)Virginia Commonwealth University Health System, Richmond, VA; (2)Allegheny General Hospital, Pittsburgh, PA

231. Hospital production of custom vascular endoprosthesis: an economical perspective.

*Luc Nguyen-Kim, PharmD*, Julien Molina, PharmD, Catherine Fargeot, PharmD, Caroline Desjardins, Resident, Robert Farinotti, PharmD, PHD, Marie E. Joel, PharmD, Fabien Koskas, MDPHD; Groupe hospitalier de la Pitié Salpêtrière, Paris, France

### Pharmacoepidemiology

232. The role of clinical team pharmacist of San Giovanni Battista Hospital in a retrospective study invasive fungine infections: management and appropriateness.

*Francesco Cattel, Dr*, Massimo Massaia, Dr, Matilde Scaldaferri, Dr, Candida Vitale, Dr, Maria Elisa Canepari, Dr, Angelo Potenzieri, Dr, Sara Boffa, Dr, Eleonora Cerutti, Dr, Evelyn Janet Pennone, Dr, Elisa Sciorsci, Dr, Giovanna Fazzina, Dr, Diego Barilà, Dr, Alessia Chiesa, Dr, Silvana Stecca, Dr; San Giovanni Battista Hospital, Turin, Italy

### Pharmacokinetics/Pharmacodynamics

233. A revised vancomycin dosing protocol to meet new IDSA guidelines.

*Tina H. Denetclaw, Pharm.D., BCPS*<sup>1</sup>, Monica Chan, Pharm.D., Candidate<sup>1</sup>, Lily Phuong, Pharm.D., Candidate<sup>1</sup>, Bonnie Le, Pharm.D., Candidate<sup>2</sup>, Homa Mirzazadeh, PharmD, Candidate<sup>3</sup>; (1)University of California at San Francisco School of Pharmacy, San Francisco, CA; (2)University of the Pacific, Stockton, CA; (3)Touro University College of Pharmacy (Mare Island), Vallejo, CA

### Primary Care

234. Addition of oral antibiotics to incision and drainage for outpatient management of bacterial skin and soft tissue abscesses: a systematic review.

Stephanie L. Ballard, Pharm.D., BCPS<sup>1</sup>, *Lisa M. Harinstein, PharmD*<sup>2</sup>, Gretchen Shelesky, MD<sup>3</sup>, Rachelle M. Busby, Pharm.D., BCPS<sup>4</sup>, Keiichiro Narumoto, MD<sup>3</sup>, Ahlam Saleh, MD, MLS<sup>5</sup>; (1)Nova Southeastern University, Palm Beach Gardens, FL; (2)UPMC

Presbyterian, Pittsburgh, PA; (3)University of Pittsburgh School of Medicine Department of Family Medicine, Pittsburgh, PA; (4)UPMC St. Margaret, Pittsburgh, PA; (5)University of Pittsburgh Health Sciences Library System, Pittsburgh, PA

### Transplant/Immunology

235. Single nucleotide polymorphisms of new diabetes-susceptible genes and post-transplant diabetes mellitus in kidney transplant patients.

*Jae-Wook Yang, Ph.D., Pharm.D*<sup>1</sup>, Therese Reignier, PhD<sup>2</sup>, Ian V. Hutchinson, PhD<sup>3</sup>, David Min, Pharm.D<sup>4</sup>; (1)University of Kansas, Kansas City, KS; (2)National Institute of Transplantation, Los Angeles, CA; (3)USC School of Pharmacy, Los Angeles, CA; (4)Western University of Health Sciences, College of Pharmacy, Pomona, CA